High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy
Zhuo Xing, Tiejun Yang, Xurui Li, Haozhe Xu, Yulong Hong, Shuai Shao, Tao Li, Liefu Ye, Yuan Li, Xin Jin, Yongbao Wei
Abstract
A-dependent manner, subsequently decreasing NECTIN4 expression and EV responsiveness. Our study identifies a high-glucose-associated lactate-AARS1-YTHDC1-JUND-NECTIN4 axis that affects EV sensitivity in BC. Targeting this axis with JUND activators or β-alanine may offer therapeutic strategies to enhance the sensitivity of BC cells to EV.
Topics & Concepts
Bladder cancerInternal medicineCancer therapyMedicineOncologyCancer researchChemistryCancerRNA modifications and cancerBladder and Urothelial Cancer TreatmentsEpigenetics and DNA Methylation